Table 1 Clinical characteristics of patients with Guillain-Barré syndrome showing hyperCKemia or normal CK levels.
From: Association between hyperCKemia and axonal degeneration in Guillain–Barré syndrome
HyperCKemia (n = 18) | Normal CK levels (n = 36) | p-value | |
|---|---|---|---|
Male/female | 12/6 | 22/14 | 0.69 |
Age (years) | 56.1 ± 12.1 | 59.4 ± 14.4 | 0.38 |
Statin use (%) | 4 (22.2) | 10 (27.7) | 0.14 |
Preceding infection (%) | 0.32 | ||
URI | 5 (27.8) | 11 (30.6) | |
Diarrhea | 8 (44.4) | 17 (47.2) | |
URI & diarrhea | 2 (11.1) | 0 | |
Operation | 0 | 1 (2.8) | |
None | 3 (16.7) | 8 (22.2) | |
Absence of sensory symptom (%) | 6 (33.3) | 8 (22.2) | 0.28 |
Presence of bulbar symptoms (%) | 4 (22.2) | 11 (30.5) | 0.53 |
Presence of facial palsy (%) | 2 (11.1) | 6 (16.7) | 0.60 |
CSF total protein level (mg/dl) (range) | 50.3 ± 23.5 (18–140) | 62.2 ± 36.2 (30–94) | 0.52 |
Periods from onset to nadir (days) | 5.8 ± 2.7 | 7.3 ± 3.0 | 0.08 |
Periods from onset to IVIG treatment (days) | 3.6 ± 2.6 | 6.9 ± 10.2 | 0.08 |
Serum CK (IU/L) (range) | 385.9 ± 185.0 (200–802) | 110.1 ± 48.6 (31–183) | 0.00* |
Periods from onset to CK measurement (days) (range) | 3.5 ± 2.7 (1–10) | 5.4 ± 5.2 (0–20) | 0.34 |
Number of antiganglioside antibodies (%) | 3/14 (21.4) | 2/27 (7.4) | 0.20 |
Hughes score at nadir | 3.9 ± 1.0 (1–5) | 3.5 ± 1.1 (1–5) | 0.29 |
Hughes score at 1 month | 2.8 ± 1.4 (1–5) | 2.6 ± 1.2 (1–5) | 0.60 |
Hughes score at 6 months | 1.6 ± 1.6 (0–4) | 1.1 ± 1.3 (0–4) | 0.26 |